{"name": "Vaximm",
 "permalink": "vaximm",
 "crunchbase_url": "http://www.crunchbase.com/company/vaximm",
 "homepage_url": "http://www.vaximm.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "",
 "description": "",
 "created_at": "Wed Jan 12 09:21:21 UTC 2011",
 "updated_at": "Wed Jan 12 09:21:20 UTC 2011",
 "overview": "\u003Cp\u003EVAXIMM is a privately held, Swiss-based vaccine company that is primarily focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Our initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. VXM01 has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA to develop VXM01. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[107,
       32],
      "assets/images/resized/0011/6958/116958v1-max-150x150.png"],
     [[107,
       32],
      "assets/images/resized/0011/6958/116958v1-max-250x250.png"],
     [[107,
       32],
      "assets/images/resized/0011/6958/116958v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Executive Chairman",
    "person":
     {"first_name": "Klaus",
      "last_name": "Breiner",
      "permalink": "klaus-breiner",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$8M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=32\u0026aid=DJFVW00020110111e71c001me\u0026r=Rss\u0026s=DJFVW",
    "source_description": "Merck Spinoff Vaximm Closes $8M Round",
    "raised_amount": 8000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 1,
    "funded_day": 12,
    "investments":
     [{"company":
        {"name": "Merck \u0026 Co.",
         "permalink": "merck-co-inc",
         "image":
          {"available_sizes":
            [[[123,
               38],
              "assets/images/resized/0004/7814/47814v3-max-150x150.jpg"],
             [[123,
               38],
              "assets/images/resized/0004/7814/47814v3-max-250x250.jpg"],
             [[123,
               38],
              "assets/images/resized/0004/7814/47814v3-max-450x450.jpg"]],
           "attribution": null}},
       "financial_org": null,
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Elisabethenstrasse 3",
    "address2": "",
    "zip_code": "4051 ",
    "city": "Basel",
    "state_code": null,
    "country_code": "CHE",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}